Recombinant Human Insulin-Like Growth Factor-1 Treatment: Ready for Primetime

George M. Bright, Jessica R. Mendoza, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The combination of targeted gene knockout studies in animals and human mutational analysis has demonstrated the key role of the IGF system in mammalian growth, both in utero and postnatally. The concept of IGF deficiency as a diagnostic category for children with growth failure first was proposed in the mid 1990s, and has gained support through the demonstration of patients with mutations in key components of the growth hormone (GH)-IGF axis, as well as the widespread use of IGF-I assays for evaluating short stature. The US Food and Drug Administration has approved IGF-I therapy for treating children who have severe primary IGF deficiency, defined as a height SD score ≤-3 and a serum IGF-1 SD score ≤-3, normal serum GH. Recent studies have demonstrated the efficacy and safety of IGF-I therapy in such patients, and investigations are in progress to determine optimal dosing. The availability of IGF-I therapy thus has expanded the therapeutic tool chest available to endocrinologists caring for children who have growth failure.

Original languageEnglish (US)
Pages (from-to)625-638
Number of pages14
JournalEndocrinology and Metabolism Clinics of North America
Volume38
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Somatomedins
Insulin-Like Growth Factor I
Growth Hormone
Growth
Therapeutics
Gene Knockout Techniques
United States Food and Drug Administration
Serum
Thorax
Safety
Mutation

Keywords

  • Growth
  • Growth hormone insensitivity
  • Insulin-like growth factor-1
  • Insulin-like growth factor-1 deficiency
  • Short stature

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Recombinant Human Insulin-Like Growth Factor-1 Treatment : Ready for Primetime. / Bright, George M.; Mendoza, Jessica R.; Rosenfeld, Ronald (Ron).

In: Endocrinology and Metabolism Clinics of North America, Vol. 38, No. 3, 09.2009, p. 625-638.

Research output: Contribution to journalArticle

Bright, George M. ; Mendoza, Jessica R. ; Rosenfeld, Ronald (Ron). / Recombinant Human Insulin-Like Growth Factor-1 Treatment : Ready for Primetime. In: Endocrinology and Metabolism Clinics of North America. 2009 ; Vol. 38, No. 3. pp. 625-638.
@article{bdc894ce3f1b412ba0c70729087fe3d3,
title = "Recombinant Human Insulin-Like Growth Factor-1 Treatment: Ready for Primetime",
abstract = "The combination of targeted gene knockout studies in animals and human mutational analysis has demonstrated the key role of the IGF system in mammalian growth, both in utero and postnatally. The concept of IGF deficiency as a diagnostic category for children with growth failure first was proposed in the mid 1990s, and has gained support through the demonstration of patients with mutations in key components of the growth hormone (GH)-IGF axis, as well as the widespread use of IGF-I assays for evaluating short stature. The US Food and Drug Administration has approved IGF-I therapy for treating children who have severe primary IGF deficiency, defined as a height SD score ≤-3 and a serum IGF-1 SD score ≤-3, normal serum GH. Recent studies have demonstrated the efficacy and safety of IGF-I therapy in such patients, and investigations are in progress to determine optimal dosing. The availability of IGF-I therapy thus has expanded the therapeutic tool chest available to endocrinologists caring for children who have growth failure.",
keywords = "Growth, Growth hormone insensitivity, Insulin-like growth factor-1, Insulin-like growth factor-1 deficiency, Short stature",
author = "Bright, {George M.} and Mendoza, {Jessica R.} and Rosenfeld, {Ronald (Ron)}",
year = "2009",
month = "9",
doi = "10.1016/j.ecl.2009.06.003",
language = "English (US)",
volume = "38",
pages = "625--638",
journal = "Endocrinology and Metabolism Clinics of North America",
issn = "0889-8529",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Recombinant Human Insulin-Like Growth Factor-1 Treatment

T2 - Ready for Primetime

AU - Bright, George M.

AU - Mendoza, Jessica R.

AU - Rosenfeld, Ronald (Ron)

PY - 2009/9

Y1 - 2009/9

N2 - The combination of targeted gene knockout studies in animals and human mutational analysis has demonstrated the key role of the IGF system in mammalian growth, both in utero and postnatally. The concept of IGF deficiency as a diagnostic category for children with growth failure first was proposed in the mid 1990s, and has gained support through the demonstration of patients with mutations in key components of the growth hormone (GH)-IGF axis, as well as the widespread use of IGF-I assays for evaluating short stature. The US Food and Drug Administration has approved IGF-I therapy for treating children who have severe primary IGF deficiency, defined as a height SD score ≤-3 and a serum IGF-1 SD score ≤-3, normal serum GH. Recent studies have demonstrated the efficacy and safety of IGF-I therapy in such patients, and investigations are in progress to determine optimal dosing. The availability of IGF-I therapy thus has expanded the therapeutic tool chest available to endocrinologists caring for children who have growth failure.

AB - The combination of targeted gene knockout studies in animals and human mutational analysis has demonstrated the key role of the IGF system in mammalian growth, both in utero and postnatally. The concept of IGF deficiency as a diagnostic category for children with growth failure first was proposed in the mid 1990s, and has gained support through the demonstration of patients with mutations in key components of the growth hormone (GH)-IGF axis, as well as the widespread use of IGF-I assays for evaluating short stature. The US Food and Drug Administration has approved IGF-I therapy for treating children who have severe primary IGF deficiency, defined as a height SD score ≤-3 and a serum IGF-1 SD score ≤-3, normal serum GH. Recent studies have demonstrated the efficacy and safety of IGF-I therapy in such patients, and investigations are in progress to determine optimal dosing. The availability of IGF-I therapy thus has expanded the therapeutic tool chest available to endocrinologists caring for children who have growth failure.

KW - Growth

KW - Growth hormone insensitivity

KW - Insulin-like growth factor-1

KW - Insulin-like growth factor-1 deficiency

KW - Short stature

UR - http://www.scopus.com/inward/record.url?scp=69249122402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249122402&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2009.06.003

DO - 10.1016/j.ecl.2009.06.003

M3 - Article

C2 - 19717008

AN - SCOPUS:69249122402

VL - 38

SP - 625

EP - 638

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

SN - 0889-8529

IS - 3

ER -